MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists.

2023年5月19日 · MAFLD and CVD are two highly prevalent global public health challenges. While the proposed change in nomenclature from NAFLD to MAFLD is new, the available evidence provides support for the recommendations of this Delphi-based consensus.

2023年5月16日 · MAFLD is associated with an increased risk of cardiovascular diseases (CVD), including hypertension, atherosclerosis, cardiomyopathies, and chronic kidney disease. While clinical data have demonstrated the link between MAFLD and the increased risk of CVD development, the mechanisms responsible for this increased risk remain unknown.

2025年3月1日 · Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is a newly proposed concept that shares common metabolic risk factors with cardiovascular disease. This study aimed to investigate the association between MAFLD and adverse cardiovascular outcomes in coronary heart disease (CHD) patients with LDL-C<1.8 mmol/L.

2025年3月19日 · A total of 340,998 participants in the UK Biobank study were included. Multivariable Cox proportional hazards models were used to estimate the effect of MAFLD and MASLD on the outcomes of cardiovascular diseases (CVDs) (coronary artery disease, stroke, heart failure, and CVD-related death) with hazard ratios …

In terms of coronary risk surrogates, the MAFLD or NAFLD population had a significantly higher proportion of subjects with CACS > 100, coronary artery disease, higher grade of coronary artery stenosis, and higher 10-year ASCVD risk (all, p < 0.05) than their counterparts.

2023年10月30日 · 摘要: 代谢相关脂肪性肝病（MAFLD）是全球范围内常见的慢性肝病，影响全球超过四分之一的成年人口。 MAFLD特征是肝脏脂肪变性和代谢紊乱共存。 作为一种代谢功能障碍性疾病，MAFLD与心血管疾病（CVD）有着相似的发病机制。 这两种疾病都与肥胖、2型糖尿病和致动脉粥样硬化性血脂异常等公认的心血管危险因素密切相关。 越来越多的证据支持MAFLD与CVD之间存在密切联系。 然而，作为一种新兴的CVD危险因素，MAFLD与传统的CVD危险因 …

代谢功能障碍相关脂肪性肝病(metabolic dysfunction-associated fatty liver disease, MAFLD)是最普遍的慢性肝病之一,但MAFLD 患者死于心血管疾病(cardiovascular disease, CVD)的频率高于肝脏疾病本身。 与MAFLD 相关的病理生理研究表明存在与CVD相关的潜在机制,涉及全身炎症、氧化应激、胰岛素抵抗(insulin resistance, IR) 、糖脂代谢、肾素– 血管紧张素系统(rein-angiotensin system, RAAS) 和交感神经系统(sympathetic nervous system, SNS) 、肠道微生物群以及遗传,促进CVD …

glp－1ra可用于治疗患有mafld的t2dm患者，在改善cvd预后方面具有公认的疗效，它可降低主要cvd不良事件、降低cvd病死率和全因死亡风险，且无明显的安全性问题。

recent studies have shown that MAFLD is a predictor of adverse CVD outcomes, independent of traditional risk fac-tors [10]. Increasing evidence now supports a link between MAFLD and CVD, and the importance of this association is well recognized among Hepatologists [11– 14]. However, MAFLD as a novel CVD risk factor remains underappreci-